The cardioprotective role of β-blockers in patients with diabetes mellitus

Journal of Clinical Pharmacy and Therapeutics

Volumn 27, Issue 4, 2002, Pages 233-242

  Landray, M J ^a   Toescu, V ^a   Kendall, M J ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

blocker; Cardioprotection; Coronary heart disease; Diabetes mellitus; Sudden death

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LABETALOL; METOPROLOL; NADOLOL; NIFEDIPINE; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; SULFONYLUREA; TIMOLOL; TRIACYLGLYCEROL;

AUTONOMIC DYSFUNCTION; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; DRUG USE; DRUG UTILIZATION; FEAR; GLUCOSE TOLERANCE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; IMPOTENCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PERFUSION PRESSURE; QUALITY OF LIFE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DIABETES COMPLICATIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES;

EID: 0036373290     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2002.00419.x     Document Type: Review

References (82)

1. Diabetes and cardiovascular disease. The Framingham study
2. Mortality from coronary heart disease in the Tecumseh study: Long-term effect of diabetes mellitus, glucose tolerance and other risk factors
3. Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study
4. A prospective study of maturity onset diabetes and risk of coronary heart disease and stroke in women
5. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
6. Treating the diabetic patient with coronary disease
7. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels
8. Changes in blood coagulation, platelet function and plasminogen-plasmin system in diabetes
9. Platelet hyper-reactivity in diabetics: Relation to the time of onset of myocardial infarction
10. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients
11. Factors of the hemostatic system in diabetic patients. A survey of controlled studies
12. Exertional myocardial ischaemia in diabetes: A quantitative analysis of anginal perceptional threshold and the influence of autonomic function
13. The diabetic heart: Metabolic causes for the development of a cardiomyopathy
14. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus
15. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis
16. Frequency domain measures of heart period variability to assess risk late after myocardial infarction
17. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal averaged electrocardiogram
18. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
19. The natural history of diabetic autonomic neuropathy
20. Prediction of sudden cardiac death in diabetic autonomic neuropathy
21. Haemodynamic modifications of aortic atherosclerosis: Effects of propranolol versus hydralazine in hypertensive hyperlipidaemic rabbits
22. Inhibition of coronary atherosclerosis by propranolol in behaviourally predisposed monkeys fed an atherogenic diet
23. Endothelial dysfunction in response to psychosocial stress in monkeys
24. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury
25. Importance of free fatty acids as determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs
26. 1 adrenoceptor activation
27. β-Blockers and sudden cardiac death
28. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade
29. Long-term beta-blockade in dilated cardiomyopathy
30. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized double-blind, placebo-controlled study
31. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
32. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
33. Regulation of cardiac vulnerability by the cerebral defence system
34. Cardiac vagal activity: A target for intervention in heart disease
35. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta blockade
36. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs
37. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through the augmentation of cardiac vagal tone
38. MRC trial of treatment of mild hypertension: Principal results
39. British MRC trial of treatment for mild hypertension - A more favourable interpretation
40. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study
41. Metoprolol in acute myocardial infarction (MIAMI): A randomised placebo-controlled international trial
42. Timolol-induced reduction in mortality and rein-farction in patients surviving acute myocardial infarction
43. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction
44. Effect on mortality of metoprolol in acute myocardial infarction
45. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results
46. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials
47. Beta-blockade during and after myocardial infarction: An overview of the randomized trials
48. Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY study
49. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
50. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
51. Timolol treatment after myocardial infarction in diabetic patients
52. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
53. β-Blockers after myocardial infarction - For few patients, or many?
54. Usefulness of beta-blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease
55. Heart disease in diabetes mellitus
56. Diabetic patients and beta-blockers after acute myocardial infarction
57. Use of secondary prophylaxis against myocardial infarction in the north of England
58. Beta-blocker therapy in acute myocardial infarction: Evidence of underutilization in the elderly
59. Physician use of beta-adrenergic blocking therapy: A changing perspective
60. Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice
61. Reducing the risk for coronary events and stroke in hypertensive patients: Comments on present evidence
62. Primary prevention with β-blockade in patients with hypertension: Review of results and clinical implications
63. Modification by propranolol of cardiovascular effects of induced hypoglycaemia
64. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycaemia in insulin-dependent diabetics
65. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas
66. The effect of antihypertensive drugs on serum lipids and lipoproteins II: Non-diuretic drugs
67. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension - Are they of prognostic importance? Observational study
68. Beta-blockade and intermittent claudication: Placebo controlled trial of atenolol and nifedipine and their combination
69. Placebo-controlled comparison of captopril, atenolol, labetolol and pindolol in hypertension complicated by intermittent claudication
70. The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication
71. Renal effects of beta-adrenoceptor blockade
72. Randomised trial of treatment of hypertension in elderly patients in primary care
73. Medical Research Council trial of treatment of hypertension in older adults: Principal results
74. Hypertension in elderly patients. Review
75. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60-75 years
76. The efficacy of low dose metoprolol CR/ZOK in mild hypertension and in elderly patients with mild to moderate hypertension
77. Beta adrenoceptor blocking drugs and the elderly
78. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction
79. Report of Medical Research Council Working Party on mild to moderate hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension
80. European Society of Cardiology: Conference report
81. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction